Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.

被引：6
|
作者：
Smyth, Elizabeth Catherine
Turner, Nicholas C.
Pearson, Alex
Peckitt, Clare
Chau, Ian
Watkins, David J.
Starling, Naureen
Rao, Sheela
Gillbanks, Angela
Kilgour, Elaine
Sumpter, Katherine Anne
Smith, Neil R.
Cutts, Ros
Rooney, Claire
Thomas, Anne L.
Ajaz, Mazhar A.
Chua, Sue
Brown, Gina
Popat, Sanjay
Cunningham, David
机构：
[1] Royal Marsden, London, England
[2] Inst Canc Res, London SW3 6JB, England
[3] Royal Marsden Hosp, London SW3 6JJ, England
[4] AstraZeneca Oncol Innovat Med, Macclesfield, Cheshire, England
[5] Northern Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England
[6] Leicester Royal Infirm, Leicester, Leics, England
[7] Royal Surrey Cty Hosp, Guildford, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.154
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
154
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study of AZD4547 in FGFR amplified tumours: gastroesophageal cancer (GC) cohort clinical and translational results
    Smyth, E. C.
    Turner, N.
    Pearson, A.
    Peckitt, C.
    Chau, I.
    Watkins, D.
    Kilgour, E.
    Smith, N. R.
    Gillbanks, A.
    Chua, S.
    Brown, G.
    Cutts, R.
    Rooney, C.
    Llavero, N. Tarazona
    Thomas, A.
    Popat, S.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2015, 26 : 44 - 44
  • [2] Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.
    Smyth, Elizabeth Catherine
    Turner, Nicholas C.
    Peckitt, Clare
    Pearson, Alex
    Brown, Gina
    Chua, Sue
    Gillbanks, Angela
    Johnston, Stephen R. D.
    Tarazona, Noelia
    Cutts, Ros
    Kilgour, Elaine
    Rooney, Claire
    Smith, Neil R.
    Sumpter, Katherine Anne
    Ajaz, Mazhar A.
    Thomas, Anne L.
    Watkins, David
    Chau, Ian
    Popat, Sanjay
    Cunningham, David
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] FGFR: Proof-of-concept study of AZD4547 in patients with FGFR1 or FGFR2 amplified tumours.
    Smyth, Elizabeth Catherine
    Turner, Nicholas C.
    Popat, Sanjay
    Morgan, Shethah
    Owen, Kate
    Gillbanks, Angela
    Jain, Vikram Kumar
    Cunningham, David
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer
    Arkenau, Hendrik-Tobias
    Saggese, Matilde
    Hollebecque, Antoine
    Mathewson, Alastair
    Lemech, Charlotte Rose
    Landers, Donal
    Frewer, Paul
    Kilgour, Elaine
    Brooks, Nigel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
    R. C. Coombes
    P. D. Badman
    J. P. Lozano-Kuehne
    X. Liu
    I. R. Macpherson
    I. Zubairi
    R. D. Baird
    N. Rosenfeld
    J. Garcia-Corbacho
    N. Cresti
    R. Plummer
    A. Armstrong
    R. Allerton
    D. Landers
    H. Nicholas
    L. McLellan
    A. Lim
    F. Mouliere
    O. E. Pardo
    V. Ferguson
    M. J. Seckl
    Nature Communications, 13
  • [6] Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
    Coombes, R. C.
    Badman, P. D.
    Lozano-Kuehne, J. P.
    Liu, X.
    Macpherson, I. R.
    Zubairi, I
    Baird, R. D.
    Rosenfeld, N.
    Garcia-Corbacho, J.
    Cresti, N.
    Plummer, R.
    Armstrong, A.
    Allerton, R.
    Landers, D.
    Nicholas, H.
    McLellan, L.
    Lim, A.
    Mouliere, F.
    Pardo, O. E.
    Seckl, M. J.
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [7] Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
    R. C. Coombes
    P. D. Badman
    J. P. Lozano-Kuehne
    X. Liu
    I. R. Macpherson
    I. Zubairi
    R. D. Baird
    N. Rosenfeld
    J. Garcia-Corbacho
    N. Cresti
    R. Plummer
    A. Armstrong
    R. Allerton
    D. Landers
    H. Nicholas
    L. McLellan
    A. Lim
    F. Mouliere
    O. E. Pardo
    V. Ferguson
    M. J. Seckl
    Nature Communications, 14
  • [8] Phase II Trial of an Oral FGFR Inhibitor AZD4547 as Second or Third Line Therapy in Malignant Pleural Mesothelioma: Final Results of FRAME Study
    Lam, W.
    Nowak, A.
    Chen, F.
    Muruganandan, S.
    Arunachalam, S.
    Chin, M.
    Millward, M.
    Read, C.
    Murray, K.
    Creaney, J.
    Lee, Y. C. G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S342 - S342
  • [9] Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (vol 13, 3246, 2022)
    Coombes, R. C.
    Badman, P. D.
    Lozano-Kuehne, J. P.
    Liu, X.
    Macpherson, I. R.
    Zubairi, I.
    Baird, R. D.
    Rosenfeld, N.
    Garcia-Corbacho, J.
    Cresti, N.
    Plummer, R.
    Armstrong, A.
    Allerton, R.
    Landers, D.
    Nicholas, H.
    McLellan, L.
    Lim, A.
    Mouliere, F.
    Pardo, O. E.
    Ferguson, V.
    Seckl, M. J.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [10] Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.
    Andre, Fabrice
    Ranson, Malcolm
    Dean, Emma
    Varga, Andrea
    van der Noll, Ruud
    Stockman, Paul K.
    Ghiorghiu, Dana
    Kilgour, Elaine
    Smith, Paul D.
    Macpherson, Merran
    Lawrence, Peter
    Hastie, Andrew
    Schellens, Jan H. M.
    CANCER RESEARCH, 2013, 73 (08)
12345